ABT
Abbott LaboratoriesNYSEHealthcare$102.87+0.48%OpenMarket Cap: $178.76B
As of 2026-04-06
Valuation
P/E (TTM)
27.40
PEG
—
P/B
3.45
P/S
4.03
EV/EBITDA
15.93
DCF Value
$134.35
FCF Yield
4.1%
Div Yield
2.3%
Margins & Returns
Gross Margin
55.5%
Operating Margin
18.2%
Net Margin
14.7%
ROE
12.9%
ROA
11.4%
ROIC
8.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $11.46B | 57.0% | $2.25B | $1.78B | $1.02 | $0.59 |
| FY 2025 | $44.33B | 55.5% | $8.05B | $6.52B | $3.72 | $2.36 |
| Q3 2025 | $11.37B | 55.7% | $2.06B | $1.64B | $0.94 | $0.59 |
| Q2 2025 | $11.14B | 56.4% | $2.05B | $1.78B | $1.01 | $0.59 |
| Q1 2025 | $10.36B | 52.6% | $1.69B | $1.32B | $0.76 | $0.59 |
| Q4 2024 | $10.97B | 51.0% | $1.99B | $9.23B | $5.27 | $0.55 |
| FY 2024 | $41.95B | 50.8% | $6.83B | $13.40B | $7.64 | $2.20 |
| Q3 2024 | $10.63B | 51.0% | $1.82B | $1.65B | $0.94 | $0.55 |
| Q2 2024 | $10.38B | 51.1% | $1.69B | $1.30B | $0.74 | $0.55 |
| Q1 2024 | $9.96B | 50.4% | $1.39B | $1.23B | $0.70 | $0.55 |
| Q4 2023 | $10.24B | 51.3% | $1.86B | $1.59B | $0.91 | $0.51 |
| FY 2023 | $40.11B | 50.0% | $6.43B | $5.72B | $3.27 | $2.04 |